董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joshua Baltzell | 男 | Director | 47 | 14.11万美元 | 未持股 | 2017-04-26 |
| Brian E. Farley | 男 | Chairman of the Board | 59 | 16.11万美元 | 未持股 | 2017-04-26 |
| Guido Neels | 男 | Director | 68 | 未披露 | 未持股 | 2017-04-26 |
| Guido J. Neels | 男 | Director | 68 | 13.00万美元 | 未持股 | 2017-04-26 |
| Shawn T McCormick | 男 | Director | 52 | 14.61万美元 | 未持股 | 2017-04-26 |
| Robert S. White | 男 | President,CEO and Director | 55 | 192.22万美元 | 未持股 | 2017-04-26 |
| David B. Milne | 男 | Director | 54 | 12.86万美元 | 未持股 | 2017-04-26 |
| John K. Bakewell | 男 | Director | 55 | 14.32万美元 | 未持股 | 2017-04-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kevin L. Mensink | 男 | Vice President, Marketing | 44 | 未披露 | 未持股 | 2017-04-26 |
| Stephen R. Paidosh | 男 | Vice President, Operations | 54 | 未披露 | 未持股 | 2017-04-26 |
| Karen E. Peterson | 女 | Vice President, Clinical, Regulatory and Quality | 58 | 32.78万美元 | 未持股 | 2017-04-26 |
| Tim B. Petrick | 男 | Vice President, Research and Development | 49 | 未披露 | 未持股 | 2017-04-26 |
| Martha J. Christian | 女 | Vice President, Reimbursement | 53 | 未披露 | 未持股 | 2017-04-26 |
| Thomas D. Williamson | 男 | Vice President, Sales | 42 | 未披露 | 未持股 | 2017-04-26 |
| Brent A. Moen | 男 | Chief Financial Officer and Secretary | 49 | 112.49万美元 | 未持股 | 2017-04-26 |
| Robert S. White | 男 | President,CEO and Director | 55 | 192.22万美元 | 未持股 | 2017-04-26 |
| Jonelle R. Burnham | 女 | Vice President, General Counsel and Compliance Officer | 46 | 未披露 | 未持股 | 2017-04-26 |
董事简历
中英对照 | 中文 | 英文- Joshua Baltzell
-
Joshua Baltzell从2006年8月开始担任我司董事。Baltzell先生担任Split Rock Partners, LLC或Split Rock的常务董事，还担任SightLine Partners LLC或SightLine的风险合伙人。他从2004年开始在Split Rock任职，并从2014年开始在SightLine任职。Baltzell先生拥有超过20年的医疗保健行业的从业经验。在风险投资行业任职前，从2000年到2002年，Baltzell先生担任过Piper Jaffray Companies的投资银行家，他在该公司主要专注于医疗设备行业的并购，并担任SCIMED and Boston Scientific的多个营销与业务开发职位。Baltzell先生目前担任Colorescience、 EBR Systems、 Inc.、 DFINE, Inc.、 Histogenics Corporation与 RF Surgical Systems, Inc.的董事，以上公司均为私有公司。Baltzell先生在圣奥拉夫学院（St. Olaf College）获得经济学文学学士学位，并在明尼苏达大学卡尔森管理学院（University of Minnesota’s Carlson School of Management）获得工商管理硕士学位。
Joshua Baltzell has served as a member of the Board since July 2012. Mr. Baltzell is a Venture Partner at Split Rock Partners, and also serves as a Venture Partner at SightLine Partners. He has been with Split Rock since 2004 and with SightLine since 2014. Prior to his tenure in the venture capital industry, Mr. Baltzell held roles as an investment banker at Piper Jaffray Companies from 2000 to 2002 where he focused primarily on mergers and acquisitions in the medical device sector, as well as various marketing and business development positions with SCIMED and Boston Scientific. Mr. Baltzell currently serves on the boards of Magnolia Medical, ViewPoint Medical and Colorescience. Mr. Baltzell holds a B.A. in Economics from St. Olaf College and an M.B.A. from the University of Minnesota’s Carlson School of Management. - Joshua Baltzell从2006年8月开始担任我司董事。Baltzell先生担任Split Rock Partners, LLC或Split Rock的常务董事，还担任SightLine Partners LLC或SightLine的风险合伙人。他从2004年开始在Split Rock任职，并从2014年开始在SightLine任职。Baltzell先生拥有超过20年的医疗保健行业的从业经验。在风险投资行业任职前，从2000年到2002年，Baltzell先生担任过Piper Jaffray Companies的投资银行家，他在该公司主要专注于医疗设备行业的并购，并担任SCIMED and Boston Scientific的多个营销与业务开发职位。Baltzell先生目前担任Colorescience、 EBR Systems、 Inc.、 DFINE, Inc.、 Histogenics Corporation与 RF Surgical Systems, Inc.的董事，以上公司均为私有公司。Baltzell先生在圣奥拉夫学院（St. Olaf College）获得经济学文学学士学位，并在明尼苏达大学卡尔森管理学院（University of Minnesota’s Carlson School of Management）获得工商管理硕士学位。
- Joshua Baltzell has served as a member of the Board since July 2012. Mr. Baltzell is a Venture Partner at Split Rock Partners, and also serves as a Venture Partner at SightLine Partners. He has been with Split Rock since 2004 and with SightLine since 2014. Prior to his tenure in the venture capital industry, Mr. Baltzell held roles as an investment banker at Piper Jaffray Companies from 2000 to 2002 where he focused primarily on mergers and acquisitions in the medical device sector, as well as various marketing and business development positions with SCIMED and Boston Scientific. Mr. Baltzell currently serves on the boards of Magnolia Medical, ViewPoint Medical and Colorescience. Mr. Baltzell holds a B.A. in Economics from St. Olaf College and an M.B.A. from the University of Minnesota’s Carlson School of Management.
- Brian E. Farley
-
Brian E. Farley，2010年3月起，担任本公司的首席执行官；2008年11月起，担任董事；2014年11月起，担任董事长。2010年3月至2014年11月，他还担任本公司总裁。加入本公司之前，他从1995年起任职于VNUS Medical Technologies, Inc.（VNUS： Nasdaq）；1996年1月起，担任其总裁、首席执行官，直到2009年6月该公司被出售给Covidien Ltd.此前，1981-1995年间，他曾任职于Guidant Corporation、Eli Lilly and Company的医疗器械部门、Lilly Research Labs，担任过研发、临床研究、业务开发领域的多个领导职务。2009年11月起，他担任医疗器械私营公司 Neuronetics, Inc的董事；2011年6月至2014年7月，和2014年12月之后，担任其董事长。2012年3月至今，他一直担任DFINE, Inc的董事、薪酬委员会成员，这是一个医疗器械私营公司。他在Purdue University获得生物医学工程学士学位、电气工程硕士学位。
Brian E. Farley has served as a member of the company's Board of Directors since November 2008 and as our Chairman of the Board since November 2014 including as Executive Chairman from April 2015 to January 2016. He also served as our President from March 2010 to November 2014 and as our Chief Executive Officer from March 2010 to April 2015. Prior to joining Entellus Medical, Mr. Farley was employed at VNUS Medical Technologies, Inc. starting in 1995 and served as President and Chief Executive Officer of VNUS from January 1996 to June 2009 when VNUS was sold to Covidien Ltd. Prior to joining VNUS, Mr. Farley was employed from 1981 to 1995 at Guidant Corporation, in the Medical Device Division of Eli Lilly and Company, and in Lilly Research Labs in a variety of research and development, clinical research and business development leadership positions. Since November 2009 Mr. Farley has served on the board of directors of Neuronetics, Inc., a private medical device company, including as Chairman of the Board from June 2011 to July 2014 and again since December 2014. Mr. Farley has served on the Neuronetics compensation committee since 2015. From March 2012 to July 2016 Mr. Farley served on the board of directors of DFine, Inc., a private company. Mr. Farley holds both a B.S. in Engineering with an emphasis in Biomedical Engineering and an M.S. in Electrical Engineering from Purdue University. - Brian E. Farley，2010年3月起，担任本公司的首席执行官；2008年11月起，担任董事；2014年11月起，担任董事长。2010年3月至2014年11月，他还担任本公司总裁。加入本公司之前，他从1995年起任职于VNUS Medical Technologies, Inc.（VNUS： Nasdaq）；1996年1月起，担任其总裁、首席执行官，直到2009年6月该公司被出售给Covidien Ltd.此前，1981-1995年间，他曾任职于Guidant Corporation、Eli Lilly and Company的医疗器械部门、Lilly Research Labs，担任过研发、临床研究、业务开发领域的多个领导职务。2009年11月起，他担任医疗器械私营公司 Neuronetics, Inc的董事；2011年6月至2014年7月，和2014年12月之后，担任其董事长。2012年3月至今，他一直担任DFINE, Inc的董事、薪酬委员会成员，这是一个医疗器械私营公司。他在Purdue University获得生物医学工程学士学位、电气工程硕士学位。
- Brian E. Farley has served as a member of the company's Board of Directors since November 2008 and as our Chairman of the Board since November 2014 including as Executive Chairman from April 2015 to January 2016. He also served as our President from March 2010 to November 2014 and as our Chief Executive Officer from March 2010 to April 2015. Prior to joining Entellus Medical, Mr. Farley was employed at VNUS Medical Technologies, Inc. starting in 1995 and served as President and Chief Executive Officer of VNUS from January 1996 to June 2009 when VNUS was sold to Covidien Ltd. Prior to joining VNUS, Mr. Farley was employed from 1981 to 1995 at Guidant Corporation, in the Medical Device Division of Eli Lilly and Company, and in Lilly Research Labs in a variety of research and development, clinical research and business development leadership positions. Since November 2009 Mr. Farley has served on the board of directors of Neuronetics, Inc., a private medical device company, including as Chairman of the Board from June 2011 to July 2014 and again since December 2014. Mr. Farley has served on the Neuronetics compensation committee since 2015. From March 2012 to July 2016 Mr. Farley served on the board of directors of DFine, Inc., a private company. Mr. Farley holds both a B.S. in Engineering with an emphasis in Biomedical Engineering and an M.S. in Electrical Engineering from Purdue University.
- Guido Neels
-
Guido Neels，2009年11月起，担任本公司董事。他从2006年起任职于Essex Woodlands，目前是风险合伙人。加入Essex Woodlands之前，他在Guidant担任过各种管理职务，这是心血管医疗产品的开发商。2004年7月直到2005年11月退休，他担任Guidant的首席运营官，负责4个业务的全球运营：心脏节律管理、血管干预、心脏外科、血管内解决方案。2002年12月至2004年7月，他担任Guidant的总裁办公室部门主席，负责全球销售运营、企业传播、企业营销、投资者关系、政府关系。2000年1月，他被任命为Guidant的欧洲、中东、非洲与加拿大地区总裁。另外，1996-2000，他曾担任Guidant的血管干预业务全球营销副总裁；1994-1996，担任德国与中欧地区总经理。 他在比利时的University of Leuven获得业务工程学位，在Stanford University Graduate School of Business获得工商管理硕士学位。2005-2009，他担任Biopure Corporation的董事，这是一个医疗器械上市公司；2006-2008，担任另一个医疗器械上市公司Lemaitre Vascular的董事；2006年起，担任私营的医疗器械公司 Nellix Inc的董事，直到2010年12月，该公司被收购。目前，他是下列私营医疗器械公司的董事：480 Biomedical、Oraya Therapeutics、Arsenal Medical、EndGenitor Technologies、Bioventus LLC、White Pine Medical LLC，还是非营利组织Christel House International的董事。他也是Endologix的董事，及其薪酬、提名与治理委员会的成员
Guido Neels has served as a member of the company's Board of Directors since November 2009. Mr. Neels has been with Essex Woodlands Health Ventures, or Essex Woodlands, a private equity investment firm, since 2006 where he is an Operating Partner. Prior to joining Essex Woodlands, Mr. Neels served in a variety of management positions at Guidant Corporation, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005 Mr. Neels served as Guidant’s Chief Operating Officer, where he was responsible for the global operations of Guidant’s four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery and Endovascular Solutions. From December 2002 to July 2004 Mr. Neels served as Guidant’s Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. In January 2000 Mr. Neels was named Guidant’s President, Europe, Middle East, Africa and Canada. In addition, Mr. Neels served as Guidant’s Vice President, Global Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant’s General Manager, Germany and Central Europe, from 1994 to 1996. Mr. Neels has a business engineering degree from the University of Leuven in Belgium and an M.B.A. from the Stanford University Graduate School of Business. Mr. Neels served on the board of directors of Biopure Corporation, a publicly traded medical device company, from 2005 to 2009 Lemaitre Vascular, Inc., a publicly traded medical device company, from 2006 to 2008 Nellix Inc., a privately held medical device company, from 2006 until its acquisition by Endologix, Inc., in December 2010 and Oraya Therapeutics, Inc., a privately held medical device company, from January 2007 to April 2016. Mr. Neels currently serves on the board of directors of 480 Biomedical, Inc., Arsenal Medical, Inc., Bioventus LLC, and White Pine Medical LLC, all privately held medical device companies, Christel House International, a not-for-profit organization and Amici Lovaniencis, a privately held company. He also serves on the board of directors of Endologix, Inc. and AxoGen, Inc., both public companies. He chairs the compensation committee and serves on the nominating, governance and compliance committee of Endologix, Inc. and chairs the compensation committee and serves on the governance and nominating committee of AxoGen, Inc. - Guido Neels，2009年11月起，担任本公司董事。他从2006年起任职于Essex Woodlands，目前是风险合伙人。加入Essex Woodlands之前，他在Guidant担任过各种管理职务，这是心血管医疗产品的开发商。2004年7月直到2005年11月退休，他担任Guidant的首席运营官，负责4个业务的全球运营：心脏节律管理、血管干预、心脏外科、血管内解决方案。2002年12月至2004年7月，他担任Guidant的总裁办公室部门主席，负责全球销售运营、企业传播、企业营销、投资者关系、政府关系。2000年1月，他被任命为Guidant的欧洲、中东、非洲与加拿大地区总裁。另外，1996-2000，他曾担任Guidant的血管干预业务全球营销副总裁；1994-1996，担任德国与中欧地区总经理。 他在比利时的University of Leuven获得业务工程学位，在Stanford University Graduate School of Business获得工商管理硕士学位。2005-2009，他担任Biopure Corporation的董事，这是一个医疗器械上市公司；2006-2008，担任另一个医疗器械上市公司Lemaitre Vascular的董事；2006年起，担任私营的医疗器械公司 Nellix Inc的董事，直到2010年12月，该公司被收购。目前，他是下列私营医疗器械公司的董事：480 Biomedical、Oraya Therapeutics、Arsenal Medical、EndGenitor Technologies、Bioventus LLC、White Pine Medical LLC，还是非营利组织Christel House International的董事。他也是Endologix的董事，及其薪酬、提名与治理委员会的成员
- Guido Neels has served as a member of the company's Board of Directors since November 2009. Mr. Neels has been with Essex Woodlands Health Ventures, or Essex Woodlands, a private equity investment firm, since 2006 where he is an Operating Partner. Prior to joining Essex Woodlands, Mr. Neels served in a variety of management positions at Guidant Corporation, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005 Mr. Neels served as Guidant’s Chief Operating Officer, where he was responsible for the global operations of Guidant’s four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery and Endovascular Solutions. From December 2002 to July 2004 Mr. Neels served as Guidant’s Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. In January 2000 Mr. Neels was named Guidant’s President, Europe, Middle East, Africa and Canada. In addition, Mr. Neels served as Guidant’s Vice President, Global Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant’s General Manager, Germany and Central Europe, from 1994 to 1996. Mr. Neels has a business engineering degree from the University of Leuven in Belgium and an M.B.A. from the Stanford University Graduate School of Business. Mr. Neels served on the board of directors of Biopure Corporation, a publicly traded medical device company, from 2005 to 2009 Lemaitre Vascular, Inc., a publicly traded medical device company, from 2006 to 2008 Nellix Inc., a privately held medical device company, from 2006 until its acquisition by Endologix, Inc., in December 2010 and Oraya Therapeutics, Inc., a privately held medical device company, from January 2007 to April 2016. Mr. Neels currently serves on the board of directors of 480 Biomedical, Inc., Arsenal Medical, Inc., Bioventus LLC, and White Pine Medical LLC, all privately held medical device companies, Christel House International, a not-for-profit organization and Amici Lovaniencis, a privately held company. He also serves on the board of directors of Endologix, Inc. and AxoGen, Inc., both public companies. He chairs the compensation committee and serves on the nominating, governance and compliance committee of Endologix, Inc. and chairs the compensation committee and serves on the governance and nominating committee of AxoGen, Inc.
- Guido J. Neels
-
Guido J. Neels自2015年8月起担任Axogen, Inc.的董事会成员。他一直担任EW Healthcare Partners L.P.的运营合伙人《娱乐周刊》自2013年2月开播。Neels先生于2006年8月加入EW担任合伙人，2008年晋升为董事总经理，直到被任命为运营合伙人。从2004年5月到2005年11月退休Neels先生担任首席运营官Guidant公司（“Guidant”），一个世界领导人在心血管医疗产品的发展，在那里他负责Guidant全球业务的四个操作单位——心脏节律管理、血管介入、心脏手术，和血管内的解决方案。从2002年12月到2004年5月，他担任Guidant总裁办公室的集团主席，负责全球销售运营、企业沟通、企业营销、投资者关系和政府关系。从2000年1月到2002年12月，他担任Guidant欧洲、中东、非洲和加拿大的总裁。Neels先生此前曾担任血管干预全球营销副总裁，以及德国和中欧业务的董事总经理。从1982年到1994年，直到Guidant从Eli Lilly和Co.分离出来成为一个独立的上市公司，他在美国和欧洲的Eli Lilly担任综合管理、销售和营销职位。从1972年到1980年，他在比利时和美国的Raychem Corporation担任信息技术、金融和制造职位。Neels先生目前任职于EW的某些投资组合公司的董事会，包括Entellus Medical, Endologix和Bioventus。此外，他还担任非营利组织Christel House International和Amici lovaniens的董事会成员，并担任丹麦Novo Holdings的顾问。他持有斯坦福大学（Stanford University）的工商管理硕士学位和比利时鲁汶大学（University of Leuven）的商业工程学位。
Guido J. Neels,has served as a member of Axogen, Inc. Board of Directors since August 2015. He has been an operating partner of EW Healthcare Partners L.P. ("EW") since February 2013. Mr. Neels joined EW as a Partner in August 2006, was promoted to Managing Director in 2008 and served in that position until being appointed to Operating Partner. From May 2004 through his retirement in November 2005, Mr. Neels served as Chief Operating Officer of Guidant Corporation ("Guidant"), a world leader in the development of cardiovascular medical products, where he was responsible for the global operations of Guidant's four operating units – Cardiac Rhythm Management,Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 through May 2004, Mr. Neels was Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 through December 2002, Mr. Neels was President of Guidant for Europe, Middle East, Africa and Canada. Mr. Neels previously served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. From 1982 through 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co. (NYSE: LLY), Mr. Neels held general management, sales and marketing positions at Eli Lilly in the United States and Europe. From 1972 through 1980, he held positions in information technology, finance and manufacturing at Raychem Corporation in Belgium and the United States. Mr. Neels currently serves on the board of directors of Bioventus LLC, a portfolio company of Essex Woodlands. In addition, Mr. Neels also serves on the board of directors for Christel House International and Amici Lovanienses, both not-for-profit organizations. Mr. Neels holds an M.B.A. from Stanford University and a business engineering degree from the University of Leuven in Belgium. - Guido J. Neels自2015年8月起担任Axogen, Inc.的董事会成员。他一直担任EW Healthcare Partners L.P.的运营合伙人《娱乐周刊》自2013年2月开播。Neels先生于2006年8月加入EW担任合伙人，2008年晋升为董事总经理，直到被任命为运营合伙人。从2004年5月到2005年11月退休Neels先生担任首席运营官Guidant公司（“Guidant”），一个世界领导人在心血管医疗产品的发展，在那里他负责Guidant全球业务的四个操作单位——心脏节律管理、血管介入、心脏手术，和血管内的解决方案。从2002年12月到2004年5月，他担任Guidant总裁办公室的集团主席，负责全球销售运营、企业沟通、企业营销、投资者关系和政府关系。从2000年1月到2002年12月，他担任Guidant欧洲、中东、非洲和加拿大的总裁。Neels先生此前曾担任血管干预全球营销副总裁，以及德国和中欧业务的董事总经理。从1982年到1994年，直到Guidant从Eli Lilly和Co.分离出来成为一个独立的上市公司，他在美国和欧洲的Eli Lilly担任综合管理、销售和营销职位。从1972年到1980年，他在比利时和美国的Raychem Corporation担任信息技术、金融和制造职位。Neels先生目前任职于EW的某些投资组合公司的董事会，包括Entellus Medical, Endologix和Bioventus。此外，他还担任非营利组织Christel House International和Amici lovaniens的董事会成员，并担任丹麦Novo Holdings的顾问。他持有斯坦福大学（Stanford University）的工商管理硕士学位和比利时鲁汶大学（University of Leuven）的商业工程学位。
- Guido J. Neels,has served as a member of Axogen, Inc. Board of Directors since August 2015. He has been an operating partner of EW Healthcare Partners L.P. ("EW") since February 2013. Mr. Neels joined EW as a Partner in August 2006, was promoted to Managing Director in 2008 and served in that position until being appointed to Operating Partner. From May 2004 through his retirement in November 2005, Mr. Neels served as Chief Operating Officer of Guidant Corporation ("Guidant"), a world leader in the development of cardiovascular medical products, where he was responsible for the global operations of Guidant's four operating units – Cardiac Rhythm Management,Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 through May 2004, Mr. Neels was Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 through December 2002, Mr. Neels was President of Guidant for Europe, Middle East, Africa and Canada. Mr. Neels previously served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. From 1982 through 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co. (NYSE: LLY), Mr. Neels held general management, sales and marketing positions at Eli Lilly in the United States and Europe. From 1972 through 1980, he held positions in information technology, finance and manufacturing at Raychem Corporation in Belgium and the United States. Mr. Neels currently serves on the board of directors of Bioventus LLC, a portfolio company of Essex Woodlands. In addition, Mr. Neels also serves on the board of directors for Christel House International and Amici Lovanienses, both not-for-profit organizations. Mr. Neels holds an M.B.A. from Stanford University and a business engineering degree from the University of Leuven in Belgium.
- Shawn T McCormick
-
Shawn T McCormick，2012年9月加入本公司，担任首席财务官。加入本公司之前，2011年4月至2012年2月，他担任Lutonix的首席运营官，这是一个医疗器械公司，在2011年12月被C. R. Bard收购。2009年1月至2010年7月，他担任ev3 Inc.的高级副总裁、首席财务官，这是一个全球性的血管内装置公司，在2010年7月被Covidien plc收购。加入ev3之前，他是全球性医疗器械公司Medtronic的企业发展副总裁，负责该公司的全球业务开发工作。他于1992年加入Medtronic，任期内担任过各种财务和领导职位。2007年7月至2008年5月，他担任Medtronic的企业技术与新创企业部副总裁。2002年7月至2007年7月，他担任Medtronic脊髓、生物制剂与导航业务的财务副总裁。此前，他还担任过该公司的其它职务，包括企业发展总监、首席企业发展助理、经理、财务分析、高级财务分析师，及高级审计师。加入Medtronic之前，他在会计师事务所KPMG Peat Marwick工作了4年。他在University of Minnesota's Carlson School of Management获得工商管理硕士学位，在Arizona State University获得会计学士学位。他是注册会计师。
Shawn T McCormick has served as a member of our Board since January 2017. Since November 2020 Mr. McCormick has served as Chief Financial Officer of Aldevron, LLC, a technology company specializing in the manufacture of plasmid DNA, mRNA and proteins. Before Aldevron, Mr. McCormick served as Chief Financial Officer of Tornier N.V., a global orthopedic company, from September 2012 until October 2015 when Tornier merged with Wright Medical Group, Inc. Before Tornier, Mr. McCormick served as Chief Operating Officer of Lutonix, Inc., a medical device company, from April 2011 to February 2012 and as Chief Financial Officer and Senior Vice President of ev3 Inc., a global endovascular company, from January 2009 to July 2010 when ev3 was acquired by Covidien plc. From 1992 to 2009 Mr. McCormick held various positions at Medtronic, including as its Vice President, Corporate Development, where he was responsible for leading Medtronic's worldwide business development activities and VP Finance for the Spinal, Biologics and Navigation business. In addition to serving on our Board, Mr. McCormick has served on the board of directors of Nevro Corp. since 2014. Mr. McCormick also served on the board of directors of Entellus Medical, Inc. from 2014 to February 2018 and Surmodics, Inc. from 2015 to December 2020. Mr. McCormick holds a B.S. in Accounting from Arizona State University and an M.B.A. from the University of Minnesota's Carlson School of Management and is a certified public accountant inactive. He is also a National Association of Corporate Directors Fellow. - Shawn T McCormick，2012年9月加入本公司，担任首席财务官。加入本公司之前，2011年4月至2012年2月，他担任Lutonix的首席运营官，这是一个医疗器械公司，在2011年12月被C. R. Bard收购。2009年1月至2010年7月，他担任ev3 Inc.的高级副总裁、首席财务官，这是一个全球性的血管内装置公司，在2010年7月被Covidien plc收购。加入ev3之前，他是全球性医疗器械公司Medtronic的企业发展副总裁，负责该公司的全球业务开发工作。他于1992年加入Medtronic，任期内担任过各种财务和领导职位。2007年7月至2008年5月，他担任Medtronic的企业技术与新创企业部副总裁。2002年7月至2007年7月，他担任Medtronic脊髓、生物制剂与导航业务的财务副总裁。此前，他还担任过该公司的其它职务，包括企业发展总监、首席企业发展助理、经理、财务分析、高级财务分析师，及高级审计师。加入Medtronic之前，他在会计师事务所KPMG Peat Marwick工作了4年。他在University of Minnesota's Carlson School of Management获得工商管理硕士学位，在Arizona State University获得会计学士学位。他是注册会计师。
- Shawn T McCormick has served as a member of our Board since January 2017. Since November 2020 Mr. McCormick has served as Chief Financial Officer of Aldevron, LLC, a technology company specializing in the manufacture of plasmid DNA, mRNA and proteins. Before Aldevron, Mr. McCormick served as Chief Financial Officer of Tornier N.V., a global orthopedic company, from September 2012 until October 2015 when Tornier merged with Wright Medical Group, Inc. Before Tornier, Mr. McCormick served as Chief Operating Officer of Lutonix, Inc., a medical device company, from April 2011 to February 2012 and as Chief Financial Officer and Senior Vice President of ev3 Inc., a global endovascular company, from January 2009 to July 2010 when ev3 was acquired by Covidien plc. From 1992 to 2009 Mr. McCormick held various positions at Medtronic, including as its Vice President, Corporate Development, where he was responsible for leading Medtronic's worldwide business development activities and VP Finance for the Spinal, Biologics and Navigation business. In addition to serving on our Board, Mr. McCormick has served on the board of directors of Nevro Corp. since 2014. Mr. McCormick also served on the board of directors of Entellus Medical, Inc. from 2014 to February 2018 and Surmodics, Inc. from 2015 to December 2020. Mr. McCormick holds a B.S. in Accounting from Arizona State University and an M.B.A. from the University of Minnesota's Carlson School of Management and is a certified public accountant inactive. He is also a National Association of Corporate Directors Fellow.
- Robert S. White
-
Robert S. White，他曾一直担任我们的董事（2013年3月以来）。他目前担任TYRX（一家私人公司，最近被Medtronic收购，TYRX 商业化创新、植入式药物组合和设备产品集中在感染控制，包括AIGISRx抗菌信封，旨在用心脏植入电子设备减少手术部位感染）的总裁兼首席执行官。加入TYRX之前，他担任美敦力公司多个职位。在39亿美元收购脊柱治疗业务之后，他担任Medtronic Kyphon的总裁。任职美敦力公司期间，他还担任的总裁，负责理疗专家控制，以及美国全球销售和营销的副总裁，负责心脏节律疾病管理业务的商业运作。在他的职业生涯中，他任职通用电气公司和礼来公司。他持有密苏里大学的航空航天工程学士学位，以及康奈尔大学工商管理学硕士学位。董事会相信，他的重要医疗设备行业的知识和成长型企业的任职经验，对AtriCure有独特的好处，并能够提高其业务发展计划的能力。
Robert S. White has served as one of our directors since March 2013. Mr. White is an operating partner of EW Healthcare Partners since May 2018. Most recently, Mr. White served as President and Chief Executive Officer of Entellus Medical, Inc., which was acquired by Stryker Corporation in February 2018 a publicly-traded company that delivered innovative, high quality, minimally-invasive therapeutic solutions to healthcare providers and their patients who suffer from sinusitis. Prior to joining Entellus, Mr. White served as President and CEO of TYRX, a privately-held company acquired by Medtronic, Inc. TYRX commercialized innovative, implantable combination drug and device products focused on infection control. Prior to joining TYRX, Mr. White held several senior leadership positions with Medtronic, Inc. Mr. White served as President of Medtronic Kyphon following its $3.9 billion acquisition of the spinal treatment business. During his time with Medtronic, Mr. White also served as President of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as Vice President of U.S. Sales and Global Marketing. Earlier in his career, Mr. White held positions with General Electric Company and Eli Lilly and Company, among others. Mr. White recently served on the Board of Directors of HyperBranch Medical Technology, a privately-held company that develops and markets products capable of adhering tissues, promoting healing, preventing fluid and air leaks, and reducing infections, until it was acquired by Stryker Corporation in October 2018. Mr. White also served on the Board of Directors of Novadaq, a publicly-traded provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, until it was acquired by Stryker Corporation in June 2018. Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University. - Robert S. White，他曾一直担任我们的董事（2013年3月以来）。他目前担任TYRX（一家私人公司，最近被Medtronic收购，TYRX 商业化创新、植入式药物组合和设备产品集中在感染控制，包括AIGISRx抗菌信封，旨在用心脏植入电子设备减少手术部位感染）的总裁兼首席执行官。加入TYRX之前，他担任美敦力公司多个职位。在39亿美元收购脊柱治疗业务之后，他担任Medtronic Kyphon的总裁。任职美敦力公司期间，他还担任的总裁，负责理疗专家控制，以及美国全球销售和营销的副总裁，负责心脏节律疾病管理业务的商业运作。在他的职业生涯中，他任职通用电气公司和礼来公司。他持有密苏里大学的航空航天工程学士学位，以及康奈尔大学工商管理学硕士学位。董事会相信，他的重要医疗设备行业的知识和成长型企业的任职经验，对AtriCure有独特的好处，并能够提高其业务发展计划的能力。
- Robert S. White has served as one of our directors since March 2013. Mr. White is an operating partner of EW Healthcare Partners since May 2018. Most recently, Mr. White served as President and Chief Executive Officer of Entellus Medical, Inc., which was acquired by Stryker Corporation in February 2018 a publicly-traded company that delivered innovative, high quality, minimally-invasive therapeutic solutions to healthcare providers and their patients who suffer from sinusitis. Prior to joining Entellus, Mr. White served as President and CEO of TYRX, a privately-held company acquired by Medtronic, Inc. TYRX commercialized innovative, implantable combination drug and device products focused on infection control. Prior to joining TYRX, Mr. White held several senior leadership positions with Medtronic, Inc. Mr. White served as President of Medtronic Kyphon following its $3.9 billion acquisition of the spinal treatment business. During his time with Medtronic, Mr. White also served as President of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as Vice President of U.S. Sales and Global Marketing. Earlier in his career, Mr. White held positions with General Electric Company and Eli Lilly and Company, among others. Mr. White recently served on the Board of Directors of HyperBranch Medical Technology, a privately-held company that develops and markets products capable of adhering tissues, promoting healing, preventing fluid and air leaks, and reducing infections, until it was acquired by Stryker Corporation in October 2018. Mr. White also served on the Board of Directors of Novadaq, a publicly-traded provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, until it was acquired by Stryker Corporation in June 2018. Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University.
- David B. Milne
-
David B. Milne，是SVLS的一位管理合伙人。于2005年加入SVLS；曾在数家大型公共和私营医疗技术公司工作的他，拥有着25年的医疗行业经验。1999年一直到2005年加入SVLS之前，他在BSC担任商业开发副总裁，负责着超过50个交易额超过近20亿美元的收购、股权投资和发展伙伴关系。他目前分别在AqueSys, Inc., Altura Medical股份有限公司、EBR Systems股份有限公司、Entellus Medical股份有限公司、ReShape Medical股份有限公司和Spinal Kinetics有限责任公司的董事会任职。此前曾在Scimed Life Systems、Becton Dickinson 和Parker Laboratories工作。他拥有从New York大学获得的市场营销/财务专业工商管理硕士学位，以及从Rutgers大学获得的生物学学士学位。
David B. Milne has served as a member of the company's Board of Directors since August 2006. Mr. Milne is a Venture Partner at SV Life Sciences Advisers, LLC, or SVLS, which is a life sciences venture capital firm. From February 2015 to December 2016 Mr. Milne served as a Managing Partner of SVLS. From 1999 until joining SVLS in February 2005 he held the position of Vice President of Corporate Business Development at Boston Scientific Corporation. Mr. Milne currently sits on the board of directors of EBR Systems, Inc., ReShape Medical, Inc., and Spinal Kinetics, Inc., all privately held companies, and TransEnterix, Inc., a publicly traded medical device company. Mr. Milne serves on the audit committee and the corporate governance and nominating committee of TransEnterix. In addition, Mr. Milne previously served on the board of directors AqueSys, Inc., Altura Medical, Inc., Sadra Medical, Inc., MindFrame, Inc., NovaLign, Inc. and CardioMind, Inc., all privately held companies, and Lombard Medical, a publicly traded medical device company. Previously Mr. Milne worked at SCIMED Life Systems, Inc., Becton, Dickinson and Company and Parker Laboratories, Inc. He holds a B.S. in Biology from Rutgers University and an M.B.A. in Marketing/Finance from New York University. - David B. Milne，是SVLS的一位管理合伙人。于2005年加入SVLS；曾在数家大型公共和私营医疗技术公司工作的他，拥有着25年的医疗行业经验。1999年一直到2005年加入SVLS之前，他在BSC担任商业开发副总裁，负责着超过50个交易额超过近20亿美元的收购、股权投资和发展伙伴关系。他目前分别在AqueSys, Inc., Altura Medical股份有限公司、EBR Systems股份有限公司、Entellus Medical股份有限公司、ReShape Medical股份有限公司和Spinal Kinetics有限责任公司的董事会任职。此前曾在Scimed Life Systems、Becton Dickinson 和Parker Laboratories工作。他拥有从New York大学获得的市场营销/财务专业工商管理硕士学位，以及从Rutgers大学获得的生物学学士学位。
- David B. Milne has served as a member of the company's Board of Directors since August 2006. Mr. Milne is a Venture Partner at SV Life Sciences Advisers, LLC, or SVLS, which is a life sciences venture capital firm. From February 2015 to December 2016 Mr. Milne served as a Managing Partner of SVLS. From 1999 until joining SVLS in February 2005 he held the position of Vice President of Corporate Business Development at Boston Scientific Corporation. Mr. Milne currently sits on the board of directors of EBR Systems, Inc., ReShape Medical, Inc., and Spinal Kinetics, Inc., all privately held companies, and TransEnterix, Inc., a publicly traded medical device company. Mr. Milne serves on the audit committee and the corporate governance and nominating committee of TransEnterix. In addition, Mr. Milne previously served on the board of directors AqueSys, Inc., Altura Medical, Inc., Sadra Medical, Inc., MindFrame, Inc., NovaLign, Inc. and CardioMind, Inc., all privately held companies, and Lombard Medical, a publicly traded medical device company. Previously Mr. Milne worked at SCIMED Life Systems, Inc., Becton, Dickinson and Company and Parker Laboratories, Inc. He holds a B.S. in Biology from Rutgers University and an M.B.A. in Marketing/Finance from New York University.
- John K. Bakewell
-
John K. Bakewell，2014年6月，他加入Lantheus担任我公司首席财务官。2013年6月至2014年5月，他曾担任Interline Brands, Inc., or Interline的首席财务官。加入Interline之前，2010年1月至2011年12月，他担任RegionalCare Hospital Partners的执行副总裁和首席财务官。此外，2000至2009年，他在全球整形外科医疗设备制造商Wright Medical Group担任相同职位。1998至2000年，他担任Altra Energy Technologies的首席财务官；1993至1998年担任Cyberonics, Inc.的首席财务官；1990至1993年担任Zeos International的首席财务官。他还是Keystone Dental, Inc.的董事会成员。他在北爱荷华大学（University of Northern Iowa）获得会计学学士学位，是明尼苏达州和爱荷华州的执业注册会计师。
John K. Bakewell has served as a member of our board of directors since November 2020. Before that, from January 2016 to November 2016 Mr. Bakewell served as the Chief Financial Officer of Exact Sciences Corporation NASDAQ: EXAS, a molecular diagnostics company. Before that, from June 2014 to December 2015 he served as Chief Financial Officer of Lantheus Holdings, Inc. (NASDAQ: LNTH), a diagnostic medical imaging company. Mr. Bakewell has also previously served at Interline Brands, Inc., RegionalCare Hospital Partners, Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020 Cyberonics, Inc., now part of LivaNova PLC (NASDAQ:LIVN), Altra Energy Technologies, Inc. and ZEOS International, Ltd. Mr. Bakewell has served as a member of the board of directors of Neuronetics, Inc. (NASDAQ: STIM), a medical technology company, since May 2020 and Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a medical device company, since February 2018. Mr. Bakewell also previously served as a member of the board of directors of Entellus Medical, Inc., now part of Stryker Corporation (NYSE: SYK), ev3 Inc., now part of Medtronic plc (NYSE: MDT) and Corindus Vascular Robotics, Inc., now a Siemens Healthineers company. Mr. Bakewell holds a BA in Accounting from the University of Northern Iowa and is a certified public accountant (current status inactive). - John K. Bakewell，2014年6月，他加入Lantheus担任我公司首席财务官。2013年6月至2014年5月，他曾担任Interline Brands, Inc., or Interline的首席财务官。加入Interline之前，2010年1月至2011年12月，他担任RegionalCare Hospital Partners的执行副总裁和首席财务官。此外，2000至2009年，他在全球整形外科医疗设备制造商Wright Medical Group担任相同职位。1998至2000年，他担任Altra Energy Technologies的首席财务官；1993至1998年担任Cyberonics, Inc.的首席财务官；1990至1993年担任Zeos International的首席财务官。他还是Keystone Dental, Inc.的董事会成员。他在北爱荷华大学（University of Northern Iowa）获得会计学学士学位，是明尼苏达州和爱荷华州的执业注册会计师。
- John K. Bakewell has served as a member of our board of directors since November 2020. Before that, from January 2016 to November 2016 Mr. Bakewell served as the Chief Financial Officer of Exact Sciences Corporation NASDAQ: EXAS, a molecular diagnostics company. Before that, from June 2014 to December 2015 he served as Chief Financial Officer of Lantheus Holdings, Inc. (NASDAQ: LNTH), a diagnostic medical imaging company. Mr. Bakewell has also previously served at Interline Brands, Inc., RegionalCare Hospital Partners, Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020 Cyberonics, Inc., now part of LivaNova PLC (NASDAQ:LIVN), Altra Energy Technologies, Inc. and ZEOS International, Ltd. Mr. Bakewell has served as a member of the board of directors of Neuronetics, Inc. (NASDAQ: STIM), a medical technology company, since May 2020 and Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a medical device company, since February 2018. Mr. Bakewell also previously served as a member of the board of directors of Entellus Medical, Inc., now part of Stryker Corporation (NYSE: SYK), ev3 Inc., now part of Medtronic plc (NYSE: MDT) and Corindus Vascular Robotics, Inc., now a Siemens Healthineers company. Mr. Bakewell holds a BA in Accounting from the University of Northern Iowa and is a certified public accountant (current status inactive).
高管简历
中英对照 | 中文 | 英文- Kevin L. Mensink
Kevin L. Mensink，2013年4月起，担任本公司的营销副总裁。2007年1月至2013年3月，他担任GN ReSound Group的营销副总裁，这是丹麦公司GN Store Nord A/S的分部；他曾负责北美地区的营销、产品管理、技术支持与培训。2005年10月至2007年1月，他担任 GN ReSound Corp的营销分析总监。2002年5月至2005年10月，他是Thomson West企业客户部的营销经理。此前，1997年10月至2002年5月，他担任Thomson West的高级财务分析师。他在 University of St. Thomas获得工商管理、会计与经济学士学位，以及管理方向的工商管理硕士学位。
Kevin L. Mensink has served as the company's Vice President, Marketing since April 2013. From January 2007 to March 2013 Mr. Mensink served as Vice President of Marketing for GN ReSound Group, a division of GN Store Nord A/S, a Danish manufacturer of hearing instruments and audiological diagnostics equipment and headsets, where he was responsible for North America marketing, product management and technical support and training. From October 2005 to January 2007 Mr. Mensink served as Director of Marketing Analytics for GN ReSound Corp. From May 2002 to October 2005 Mr. Mensink served as Marketing Manager at Thomson West in the Corporate Segment Division. Prior to that, Mr. Mensink served as a Senior Financial Analyst at Thomson West from October 1997 to May 2002. Mr. Mensink holds a B.S. in Business Administration, Accounting and Economics and an M.B.A. in Management from the University of St. Thomas.- Kevin L. Mensink，2013年4月起，担任本公司的营销副总裁。2007年1月至2013年3月，他担任GN ReSound Group的营销副总裁，这是丹麦公司GN Store Nord A/S的分部；他曾负责北美地区的营销、产品管理、技术支持与培训。2005年10月至2007年1月，他担任 GN ReSound Corp的营销分析总监。2002年5月至2005年10月，他是Thomson West企业客户部的营销经理。此前，1997年10月至2002年5月，他担任Thomson West的高级财务分析师。他在 University of St. Thomas获得工商管理、会计与经济学士学位，以及管理方向的工商管理硕士学位。
- Kevin L. Mensink has served as the company's Vice President, Marketing since April 2013. From January 2007 to March 2013 Mr. Mensink served as Vice President of Marketing for GN ReSound Group, a division of GN Store Nord A/S, a Danish manufacturer of hearing instruments and audiological diagnostics equipment and headsets, where he was responsible for North America marketing, product management and technical support and training. From October 2005 to January 2007 Mr. Mensink served as Director of Marketing Analytics for GN ReSound Corp. From May 2002 to October 2005 Mr. Mensink served as Marketing Manager at Thomson West in the Corporate Segment Division. Prior to that, Mr. Mensink served as a Senior Financial Analyst at Thomson West from October 1997 to May 2002. Mr. Mensink holds a B.S. in Business Administration, Accounting and Economics and an M.B.A. in Management from the University of St. Thomas.
- Stephen R. Paidosh
Stephen R. Paidosh，自2007年12月起担任运营副总裁。Paidosh从1999年7月到2007年12月担任Myocor, Inc.（一家私营医疗设备公司）运营副总裁。Paidosh从1988年12月到1999年7月在SCIMED Life Systems, Inc.担任多个工程和运营领导职位，SCIMED被Boston Scientific 收购之后他在Boston Scientific Corporation担任过多个职位，最终的职位是担任International Vascular and Metallurgical Operations主管。在此之前，Paidosh曾在Pfizer Inc.子公司Schneider-Shiley USA Inc. 以及St. Jude Medical, Inc.担任多个工程职位。Paidosh持有斯托特the University of Wisconsin工业技术（制造工程）理学学士学位。
Stephen R. Paidosh has served as the company's Vice President, Operations since December 2007. From July 1999 to December 2007 Mr. Paidosh served as Vice President of Operations at Myocor, Inc., a privately held medical device company. From December 1988 to July 1999 Mr. Paidosh held various leadership positions in engineering and operations at SCIMED Life Systems, Inc. and at Boston Scientific Corporation following the acquisition of SCIMED by Boston Scientific, ending as Director of International Vascular and Metallurgical Operations. Prior to that, Mr. Paidosh held positions in engineering with Pfizer Inc.’s subsidiary Schneider-Shiley USA Inc. and at St. Jude Medical, Inc. Mr. Paidosh holds a B.S. in Industrial Technology (Manufacturing Engineering) from the University of Wisconsin, Stout.- Stephen R. Paidosh，自2007年12月起担任运营副总裁。Paidosh从1999年7月到2007年12月担任Myocor, Inc.（一家私营医疗设备公司）运营副总裁。Paidosh从1988年12月到1999年7月在SCIMED Life Systems, Inc.担任多个工程和运营领导职位，SCIMED被Boston Scientific 收购之后他在Boston Scientific Corporation担任过多个职位，最终的职位是担任International Vascular and Metallurgical Operations主管。在此之前，Paidosh曾在Pfizer Inc.子公司Schneider-Shiley USA Inc. 以及St. Jude Medical, Inc.担任多个工程职位。Paidosh持有斯托特the University of Wisconsin工业技术（制造工程）理学学士学位。
- Stephen R. Paidosh has served as the company's Vice President, Operations since December 2007. From July 1999 to December 2007 Mr. Paidosh served as Vice President of Operations at Myocor, Inc., a privately held medical device company. From December 1988 to July 1999 Mr. Paidosh held various leadership positions in engineering and operations at SCIMED Life Systems, Inc. and at Boston Scientific Corporation following the acquisition of SCIMED by Boston Scientific, ending as Director of International Vascular and Metallurgical Operations. Prior to that, Mr. Paidosh held positions in engineering with Pfizer Inc.’s subsidiary Schneider-Shiley USA Inc. and at St. Jude Medical, Inc. Mr. Paidosh holds a B.S. in Industrial Technology (Manufacturing Engineering) from the University of Wisconsin, Stout.
- Karen E. Peterson
Karen E. Peterson，2010年7月起，担任本公司的临床、监管与质量副总裁；2011年6月起，担任合规官。2010年5月至2010年7月，她还担任本公司的监管与质量副总裁。2006年11月至2010年4月，她担任Leptos Biomedical, Inc.的临床、监管与质量副总裁。此前，她在Impres Medical, Inc、Carbon Medical Technologies、XRT Corporation 、 Guidant担任过临床、监管与质量方面的多个职务。她在University of Wisconsin, Eau Claire获得化学学士学位，辅修数学；并在University of Minnesota获得生物统计学和卫生信息系统硕士学位。
Karen E. Peterson has served as the company's Vice President, Clinical, Regulatory and Quality since July 2010. From June 2011 until February 2016 she also served as our Compliance Officer. Ms. Peterson served as our Vice President of Regulatory and Quality from May 2010 to July 2010. From November 2006 to April 2010 Ms. Peterson served as Vice President of Clinical, Regulatory and Quality at Leptos Biomedical, Inc. Prior to that, Ms. Peterson held various clinical, regulatory and quality positions for Impres Medical, Inc., Carbon Medical Technologies, Inc., XRT Corporation and Guidant Corporation. Ms. Peterson holds a B.S. in Chemistry from the University of Wisconsin, Eau Claire including a Math minor and an M.S. in Biometry and Health Information Systems from the University of Minnesota.- Karen E. Peterson，2010年7月起，担任本公司的临床、监管与质量副总裁；2011年6月起，担任合规官。2010年5月至2010年7月，她还担任本公司的监管与质量副总裁。2006年11月至2010年4月，她担任Leptos Biomedical, Inc.的临床、监管与质量副总裁。此前，她在Impres Medical, Inc、Carbon Medical Technologies、XRT Corporation 、 Guidant担任过临床、监管与质量方面的多个职务。她在University of Wisconsin, Eau Claire获得化学学士学位，辅修数学；并在University of Minnesota获得生物统计学和卫生信息系统硕士学位。
- Karen E. Peterson has served as the company's Vice President, Clinical, Regulatory and Quality since July 2010. From June 2011 until February 2016 she also served as our Compliance Officer. Ms. Peterson served as our Vice President of Regulatory and Quality from May 2010 to July 2010. From November 2006 to April 2010 Ms. Peterson served as Vice President of Clinical, Regulatory and Quality at Leptos Biomedical, Inc. Prior to that, Ms. Peterson held various clinical, regulatory and quality positions for Impres Medical, Inc., Carbon Medical Technologies, Inc., XRT Corporation and Guidant Corporation. Ms. Peterson holds a B.S. in Chemistry from the University of Wisconsin, Eau Claire including a Math minor and an M.S. in Biometry and Health Information Systems from the University of Minnesota.
- Tim B. Petrick
Tim B. Petrick，2008年6月起，担任本公司的研发副总裁；2007年2月至2008年5月，担任研发经理/总监。2002年10月至2006年12月，他是Velocimed, Inc的项目工程师，该公司在2005年被St. Jude Medical, Inc收购。1998年1月至2002年7月，他在TERAMed Corporation担任过监管事务和工程方面的各种职务，该公司在2001被Johnson & Johnson的分部Cordis Corporation收购。他在North Dakota State University获得机械工程学士学位。
Tim B. Petrick has served as the company's Vice President, Research and Development since June 2008 and served in the capacity of Manager or Director of Research and Development from February 2007 to May 2008. From October 2002 to December 2006 Mr. Petrick was a Project Engineer with Velocimed, Inc. which was acquired by St. Jude Medical, Inc. in 2005. From January 1998 to July 2002 Mr. Petrick held various positions in regulatory affairs and engineering with TERAMed Corporation, which was acquired by Cordis Corporation, a division of Johnson & Johnson, in 2001. Mr. Petrick holds a B.S. in Mechanical Engineering from North Dakota State University.- Tim B. Petrick，2008年6月起，担任本公司的研发副总裁；2007年2月至2008年5月，担任研发经理/总监。2002年10月至2006年12月，他是Velocimed, Inc的项目工程师，该公司在2005年被St. Jude Medical, Inc收购。1998年1月至2002年7月，他在TERAMed Corporation担任过监管事务和工程方面的各种职务，该公司在2001被Johnson & Johnson的分部Cordis Corporation收购。他在North Dakota State University获得机械工程学士学位。
- Tim B. Petrick has served as the company's Vice President, Research and Development since June 2008 and served in the capacity of Manager or Director of Research and Development from February 2007 to May 2008. From October 2002 to December 2006 Mr. Petrick was a Project Engineer with Velocimed, Inc. which was acquired by St. Jude Medical, Inc. in 2005. From January 1998 to July 2002 Mr. Petrick held various positions in regulatory affairs and engineering with TERAMed Corporation, which was acquired by Cordis Corporation, a division of Johnson & Johnson, in 2001. Mr. Petrick holds a B.S. in Mechanical Engineering from North Dakota State University.
- Martha J. Christian
MarthaJ.Christian自2017年2月起担任公司Vice President。2015年3月至2017年2月，Christian女士担任Manitou Hill Solutions LLC（一家为医疗器械行业提供战略报销咨询服务的公司）的总裁。从2014年6月到2015年1月，她曾担任Coloplast Corporation（丹麦公司，专门从事泌尿外科和造口产品）的美国报销董事。从2001年4月到2014年4月，Christian女士担任普林斯顿报销集团（Princeton Reportation Group）的战略报销总监，这是一家企业医疗设备报销咨询公司。在担任报销顾问的这些年里，Christian女士在整个产品生命周期中与广泛的产品合作，以促进成功的市场采用和扩展。Christian女士的职业生涯始于进入医疗器械行业之前担任健康设施管理员。Christian女士拥有明尼苏达州立大学曼卡托分校（Minnesota State University，Mankato）的硕士学位和圣奥拉夫学院（St.Olaf College）的政治学学士学位。
Martha J. Christian has served as the company's Vice President, Reimbursement since February 2017. From March 2015 to February 2017 Ms. Christian served as President of Manitou Hill Solutions LLC, a company providing strategic reimbursement consulting services to the medical device industry. From June 2014 to January 2015 she served as Director of US Reimbursement at Coloplast Corporation, a Danish company specializing in urology and ostomy products. From April 2001 to April 2014 Ms. Christian served as Director of Strategic Reimbursement at Princeton Reimbursement Group, a corporate medical device reimbursement consulting firm. Over the years as a reimbursement consultant, Ms. Christian has worked with a broad range of products throughout the product life cycle to facilitate successful market adoption and expansion. Ms. Christian began her career as a health facility administrator before entering the medical device industry. Ms. Christian holds a M.S. in Continuing Studies from Minnesota State University, Mankato and a B.S. in Political Science from St. Olaf College.- MarthaJ.Christian自2017年2月起担任公司Vice President。2015年3月至2017年2月，Christian女士担任Manitou Hill Solutions LLC（一家为医疗器械行业提供战略报销咨询服务的公司）的总裁。从2014年6月到2015年1月，她曾担任Coloplast Corporation（丹麦公司，专门从事泌尿外科和造口产品）的美国报销董事。从2001年4月到2014年4月，Christian女士担任普林斯顿报销集团（Princeton Reportation Group）的战略报销总监，这是一家企业医疗设备报销咨询公司。在担任报销顾问的这些年里，Christian女士在整个产品生命周期中与广泛的产品合作，以促进成功的市场采用和扩展。Christian女士的职业生涯始于进入医疗器械行业之前担任健康设施管理员。Christian女士拥有明尼苏达州立大学曼卡托分校（Minnesota State University，Mankato）的硕士学位和圣奥拉夫学院（St.Olaf College）的政治学学士学位。
- Martha J. Christian has served as the company's Vice President, Reimbursement since February 2017. From March 2015 to February 2017 Ms. Christian served as President of Manitou Hill Solutions LLC, a company providing strategic reimbursement consulting services to the medical device industry. From June 2014 to January 2015 she served as Director of US Reimbursement at Coloplast Corporation, a Danish company specializing in urology and ostomy products. From April 2001 to April 2014 Ms. Christian served as Director of Strategic Reimbursement at Princeton Reimbursement Group, a corporate medical device reimbursement consulting firm. Over the years as a reimbursement consultant, Ms. Christian has worked with a broad range of products throughout the product life cycle to facilitate successful market adoption and expansion. Ms. Christian began her career as a health facility administrator before entering the medical device industry. Ms. Christian holds a M.S. in Continuing Studies from Minnesota State University, Mankato and a B.S. in Political Science from St. Olaf College.
- Thomas D. Williamson
ThomasD.Williamson自2017年1月5日起担任公司Vice President。从2011年12月至2017年1月，威廉森先生担任我们的区域销售Vice President。在加入Entellus Medical之前，Williamson先生曾担任史赛克公司公司的全国销售总监。Williamson先生拥有路易斯安那州立大学（Louisiana State University）化学工程学士学位。
Thomas D. Williamson has served as the company's Vice President, Sales since January 5 2017. From December 2011 to January 2017 Mr. Williamson served as our Regional Vice President, Sales. Prior to joining Entellus Medical, Mr. Williamson served as National Sales Director for Stryker Corporation. Mr. Williamson holds a B.S. in Chemical Engineering from Louisiana State University.- ThomasD.Williamson自2017年1月5日起担任公司Vice President。从2011年12月至2017年1月，威廉森先生担任我们的区域销售Vice President。在加入Entellus Medical之前，Williamson先生曾担任史赛克公司公司的全国销售总监。Williamson先生拥有路易斯安那州立大学（Louisiana State University）化学工程学士学位。
- Thomas D. Williamson has served as the company's Vice President, Sales since January 5 2017. From December 2011 to January 2017 Mr. Williamson served as our Regional Vice President, Sales. Prior to joining Entellus Medical, Mr. Williamson served as National Sales Director for Stryker Corporation. Mr. Williamson holds a B.S. in Chemical Engineering from Louisiana State University.
- Brent A. Moen
Brent A. Moen于2011年被任命为高级副总裁兼首席财务官。他曾担任副总裁兼公司总会计师（从2006年到2011年）、财务副总裁（从2002年到2006年）、财务董事（从2000年到2002年）。
Brent A. Moen has served as the company's Chief Financial Officer and Secretary since May 2016. From November 2013 to May 2015 Mr. Moen served as Executive Vice President and Chief Financial Officer of ABRA Auto Body & Glass LP, an auto body and glass company. From January 2011 to December 2012 Mr. Moen served as Senior Vice President and Chief Financial Officer of Regis Corporation, a publicly held owner, franchisor and operator of beauty salons. From 2000 to January 2011 Mr. Moen held various financial roles of increasing responsibility with Regis Corporation. Mr. Moen holds a B.A. in Accounting from the University of North Dakota.- Brent A. Moen于2011年被任命为高级副总裁兼首席财务官。他曾担任副总裁兼公司总会计师（从2006年到2011年）、财务副总裁（从2002年到2006年）、财务董事（从2000年到2002年）。
- Brent A. Moen has served as the company's Chief Financial Officer and Secretary since May 2016. From November 2013 to May 2015 Mr. Moen served as Executive Vice President and Chief Financial Officer of ABRA Auto Body & Glass LP, an auto body and glass company. From January 2011 to December 2012 Mr. Moen served as Senior Vice President and Chief Financial Officer of Regis Corporation, a publicly held owner, franchisor and operator of beauty salons. From 2000 to January 2011 Mr. Moen held various financial roles of increasing responsibility with Regis Corporation. Mr. Moen holds a B.A. in Accounting from the University of North Dakota.
- Robert S. White
Robert S. White，他曾一直担任我们的董事（2013年3月以来）。他目前担任TYRX（一家私人公司，最近被Medtronic收购，TYRX 商业化创新、植入式药物组合和设备产品集中在感染控制，包括AIGISRx抗菌信封，旨在用心脏植入电子设备减少手术部位感染）的总裁兼首席执行官。加入TYRX之前，他担任美敦力公司多个职位。在39亿美元收购脊柱治疗业务之后，他担任Medtronic Kyphon的总裁。任职美敦力公司期间，他还担任的总裁，负责理疗专家控制，以及美国全球销售和营销的副总裁，负责心脏节律疾病管理业务的商业运作。在他的职业生涯中，他任职通用电气公司和礼来公司。他持有密苏里大学的航空航天工程学士学位，以及康奈尔大学工商管理学硕士学位。董事会相信，他的重要医疗设备行业的知识和成长型企业的任职经验，对AtriCure有独特的好处，并能够提高其业务发展计划的能力。
Robert S. White has served as one of our directors since March 2013. Mr. White is an operating partner of EW Healthcare Partners since May 2018. Most recently, Mr. White served as President and Chief Executive Officer of Entellus Medical, Inc., which was acquired by Stryker Corporation in February 2018 a publicly-traded company that delivered innovative, high quality, minimally-invasive therapeutic solutions to healthcare providers and their patients who suffer from sinusitis. Prior to joining Entellus, Mr. White served as President and CEO of TYRX, a privately-held company acquired by Medtronic, Inc. TYRX commercialized innovative, implantable combination drug and device products focused on infection control. Prior to joining TYRX, Mr. White held several senior leadership positions with Medtronic, Inc. Mr. White served as President of Medtronic Kyphon following its $3.9 billion acquisition of the spinal treatment business. During his time with Medtronic, Mr. White also served as President of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as Vice President of U.S. Sales and Global Marketing. Earlier in his career, Mr. White held positions with General Electric Company and Eli Lilly and Company, among others. Mr. White recently served on the Board of Directors of HyperBranch Medical Technology, a privately-held company that develops and markets products capable of adhering tissues, promoting healing, preventing fluid and air leaks, and reducing infections, until it was acquired by Stryker Corporation in October 2018. Mr. White also served on the Board of Directors of Novadaq, a publicly-traded provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, until it was acquired by Stryker Corporation in June 2018. Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University.- Robert S. White，他曾一直担任我们的董事（2013年3月以来）。他目前担任TYRX（一家私人公司，最近被Medtronic收购，TYRX 商业化创新、植入式药物组合和设备产品集中在感染控制，包括AIGISRx抗菌信封，旨在用心脏植入电子设备减少手术部位感染）的总裁兼首席执行官。加入TYRX之前，他担任美敦力公司多个职位。在39亿美元收购脊柱治疗业务之后，他担任Medtronic Kyphon的总裁。任职美敦力公司期间，他还担任的总裁，负责理疗专家控制，以及美国全球销售和营销的副总裁，负责心脏节律疾病管理业务的商业运作。在他的职业生涯中，他任职通用电气公司和礼来公司。他持有密苏里大学的航空航天工程学士学位，以及康奈尔大学工商管理学硕士学位。董事会相信，他的重要医疗设备行业的知识和成长型企业的任职经验，对AtriCure有独特的好处，并能够提高其业务发展计划的能力。
- Robert S. White has served as one of our directors since March 2013. Mr. White is an operating partner of EW Healthcare Partners since May 2018. Most recently, Mr. White served as President and Chief Executive Officer of Entellus Medical, Inc., which was acquired by Stryker Corporation in February 2018 a publicly-traded company that delivered innovative, high quality, minimally-invasive therapeutic solutions to healthcare providers and their patients who suffer from sinusitis. Prior to joining Entellus, Mr. White served as President and CEO of TYRX, a privately-held company acquired by Medtronic, Inc. TYRX commercialized innovative, implantable combination drug and device products focused on infection control. Prior to joining TYRX, Mr. White held several senior leadership positions with Medtronic, Inc. Mr. White served as President of Medtronic Kyphon following its $3.9 billion acquisition of the spinal treatment business. During his time with Medtronic, Mr. White also served as President of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as Vice President of U.S. Sales and Global Marketing. Earlier in his career, Mr. White held positions with General Electric Company and Eli Lilly and Company, among others. Mr. White recently served on the Board of Directors of HyperBranch Medical Technology, a privately-held company that develops and markets products capable of adhering tissues, promoting healing, preventing fluid and air leaks, and reducing infections, until it was acquired by Stryker Corporation in October 2018. Mr. White also served on the Board of Directors of Novadaq, a publicly-traded provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, until it was acquired by Stryker Corporation in June 2018. Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University.
- Jonelle R. Burnham
JonelleR.Burnham自2017年1月5日起担任公司Vice President、总法律顾问和合规官。从2016年2月至2017年1月，Burnham女士担任我们的高级总监，公司合规顾问-合规官。从2014年4月到2015年2月，她曾担任帕特森公司公司（上市分销商，服务于牙科和动物保健市场）的Vice President、总法律顾问兼秘书，此前曾担任副总法律顾问（2009年10月至2014年4月）。Burnham女士从2002年7月到2009年9月担任金佰利公司公司（一家全球消费品牌公司）的法律顾问、助理秘书和高级专利律师等多个职位。在加入Kimberly-Clark之前，Burnham女士是Merchant&Gould律师事务所明尼阿波利斯办事处的助理律师。Burnham女士拥有明尼苏达大学（University of Minnesota）的B.C.E.，土木工程和马凯特法学院（Marquette Law School）的法学博士学位。
Jonelle R. Burnham has served as the company's Vice President, General Counsel and Compliance Officer since January 5 2017. From February 2016 to January 2017 Ms. Burnham served as our Senior Director, Corporate Compliance Counsel - Compliance Officer. From April 2014 to February 2015 she served as Vice President, General Counsel and Secretary of Patterson Companies, Inc., a publicly held distributor serving the dental and animal health markets, and prior to such position, served as Associate General Counsel from October 2009 to April 2014. From July 2002 to September 2009 Ms. Burnham held various positions as counsel, assistant secretary and senior patent attorney for Kimberly-Clark Corporation, a global consumer brand company. Prior to joining Kimberly-Clark, Ms. Burnham was an associate attorney in the Minneapolis office of the Merchant & Gould law firm. Ms. Burnham holds a B.C.E., Civil Engineering from the University of Minnesota and a J.D. from Marquette Law School.- JonelleR.Burnham自2017年1月5日起担任公司Vice President、总法律顾问和合规官。从2016年2月至2017年1月，Burnham女士担任我们的高级总监，公司合规顾问-合规官。从2014年4月到2015年2月，她曾担任帕特森公司公司（上市分销商，服务于牙科和动物保健市场）的Vice President、总法律顾问兼秘书，此前曾担任副总法律顾问（2009年10月至2014年4月）。Burnham女士从2002年7月到2009年9月担任金佰利公司公司（一家全球消费品牌公司）的法律顾问、助理秘书和高级专利律师等多个职位。在加入Kimberly-Clark之前，Burnham女士是Merchant&Gould律师事务所明尼阿波利斯办事处的助理律师。Burnham女士拥有明尼苏达大学（University of Minnesota）的B.C.E.，土木工程和马凯特法学院（Marquette Law School）的法学博士学位。
- Jonelle R. Burnham has served as the company's Vice President, General Counsel and Compliance Officer since January 5 2017. From February 2016 to January 2017 Ms. Burnham served as our Senior Director, Corporate Compliance Counsel - Compliance Officer. From April 2014 to February 2015 she served as Vice President, General Counsel and Secretary of Patterson Companies, Inc., a publicly held distributor serving the dental and animal health markets, and prior to such position, served as Associate General Counsel from October 2009 to April 2014. From July 2002 to September 2009 Ms. Burnham held various positions as counsel, assistant secretary and senior patent attorney for Kimberly-Clark Corporation, a global consumer brand company. Prior to joining Kimberly-Clark, Ms. Burnham was an associate attorney in the Minneapolis office of the Merchant & Gould law firm. Ms. Burnham holds a B.C.E., Civil Engineering from the University of Minnesota and a J.D. from Marquette Law School.